section name header

Evidence summaries

Belimumab for Systemic Lupus Erythematosus

Belimumab reduces systemic lupus erythematosus (SLE) disease activity and glucocorticoid doses in SLE patients when compared to placebo. Level of evidence: "A"

Summary

A Cochrane review [Abstract] 1 included 6 studies with a total of 2 917 subjects (age range 22 to 80 years). Study duration ranged from 84 days to 76 weeks. More participants on belimumab 10 mg/kg showed at least a 4-point improvement (reduction) in SELENA-SLEDAI score, a validated SLE disease activity index (RR 1.33, 95% CI 1.22 to 1.45; 4 studies, n=2 666) compared to placebo (NNTB 8, 95% CI 6 to 11).There was probably little or no difference between groups in change in health-related quality of life (HRQOL), assessed by Short Form-36 Physical Component Summary score improvement (range 0 to 100) (MD 1.6 points, 95% CI 0.30 to 2.90; 2 studies, n=801). A higher proportion of participants on belimumab reduced their glucocorticoid dose by at least 50% compared to placebo (RR 1.59, 95% CI 1.17 to 2.15; 2 studies, n=537; NNTB 9, 95% CI 5 to 28).

The proportion of participants experiencing harm did not differ between the groups: one or more serious adverse event (RR 0.87, 95% CI: 0.68 to 1.11; 5 studies, n=2 890); one or more serious infection (RR 1.01, 95% CI: 0.66 to 1.54; 4 studies, n=2 185); and withdrawals due to adverse events (RR 0.82, 95% CI: 0.63 to 1.07; 5 studies, n=2 890). Mortality was rare, and did not differ between belimumab and placebo (Peto OR 1.15, 95% CI 0.41 to 3.25; 6 studies, n=2 917).

Clinical comments

Note

Date of latest search:

    References

    • Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev 2021;(2):CD010668. [PubMed]

Primary/Secondary Keywords